A Prospective Multicenter Clinical Trial on the Efficacy and Safety of RC48-ADC (Disitamab Vedotin) Combined With Toripalimab in Advanced HER2-positive Extramammary Paget Disease of the Scrotum
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs Disitamab vedotin (Primary) ; Toripalimab
- Indications Extramammary Paget disease
- Focus Therapeutic Use
- 30 Jan 2025 New trial record